{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:06:32Z","timestamp":1771362392401,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jacadv.2025.102282","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T22:27:08Z","timestamp":1761690428000},"page":"102282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Ivabradine and Atrial Fibrillation Incidence"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-7434","authenticated-orcid":false,"given":"Kibum","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmeen","family":"Keur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halie","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0750-2308","authenticated-orcid":false,"given":"Przemys\u0142aw B.","family":"Radwa\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9543-1898","authenticated-orcid":false,"given":"Mark A.","family":"Munger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacadv.2025.102282_bib1","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.jacadv.2025.102282_bib2","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1161\/CIR.0000000000000905","article-title":"Drug-Induced arrhythmias: a scientific statement from the American Heart Association","volume":"142","author":"Tisdale","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.102282_bib3","doi-asserted-by":"crossref","first-page":"ITC33","DOI":"10.7326\/AITC201703070","article-title":"Atrial fibrillation","volume":"166","author":"Zimetbaum","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102282_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.hroo.2022.07.010","article-title":"Healthcare utilization and costs associated with a diagnosis of incident atrial fibrillation","volume":"3","author":"Deshmukh","year":"2022","journal-title":"Heart Rhythm O2"},{"key":"10.1016\/j.jacadv.2025.102282_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.phrs.2006.03.006","article-title":"Funny channels in the control of cardiac rhythm and mode of action of selective blockers","volume":"53","author":"DiFrancesco","year":"2006","journal-title":"Pharmacol Res"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102282_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236193","article-title":"A genetic model of ivabradine recapitulates results from randomized clinical trials","volume":"15","author":"Legault","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jacadv.2025.102282_bib8","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ng.2261","article-title":"Meta-analysis identifies six new susceptibility loci for atrial fibrillation","volume":"44","author":"Elinor","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacadv.2025.102282_bib9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/ng.2610","article-title":"Identification of heart rate-associated foci and their effects on cardiac conduction and rhythm disorders","volume":"45","author":"den Hoed","year":"2013","journal-title":"Nat Genetic"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102282_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1540-8167.2011.02209.x","article-title":"The funny current (If): is it a novel antiarrhythmic target to treat atrial fibrillation?","volume":"23","author":"Xue","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102282_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cardfail.2018.09.016","article-title":"Heart failure differentially modulates the effects of ivabradine on the electrical activity of the sinoatrial node and pulmonary veins","volume":"24","author":"Chan","year":"2018","journal-title":"J Cardiac Fail"},{"issue":"6A","key":"10.1016\/j.jacadv.2025.102282_bib12","doi-asserted-by":"crossref","first-page":"2D","DOI":"10.1016\/S0002-9149(02)03373-8","article-title":"Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy","volume":"91","author":"Maisel","year":"2003","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102282_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/FJC.0000000000001209","article-title":"Ivabradine and atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"79","author":"Wang","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"10.1016\/j.jacadv.2025.102282_bib14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/clc.22578","article-title":"The risk of atrial fibrillation with ivabradine treatment: a meta-analysis with trial sequential analysis of more than 40000 patients","volume":"39","author":"Tanbo\u011fa","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacadv.2025.102282_bib15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2010.10.065","article-title":"Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy)","volume":"107","author":"Tendera","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2025.102282_bib16","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/eurjhf\/hft102","article-title":"Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study","volume":"15","author":"Tavazzi","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"10.1016\/j.jacadv.2025.102282_bib17","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102282_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00002018-200831020-00001","article-title":"I f inhibition with ivabradine: electrophysiological effects and safety","volume":"31","author":"Savelieva","year":"2008","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102282_bib19","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0008-6363(98)00047-9","article-title":"Characterization of the hyperpolarization-activated inward current in isolated human atrial myocytes","volume":"38","author":"Hoppe","year":"1998","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102282_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1540-8167.2011.02173.x","article-title":"Effects of ivabradine on the pulmonary vein electrical activity and modulation of pacemaker currents and calcium homeostasis","volume":"23","author":"Suenari","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102282_bib21","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1002\/ehf2.13966","article-title":"Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation","volume":"9","author":"Lin","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102282_bib22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/01.ede.0000215160.88317.cb","article-title":"Instrumental variables: application and limitations","volume":"17","author":"Martens","year":"2006","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102282_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102282_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023237","article-title":"Identification of incident atrial fibrillation from electronic medical records","volume":"11","author":"Chamberlain","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"10.1016\/j.jacadv.2025.102282_bib25","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25007112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25007112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:07:51Z","timestamp":1771358871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25007112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2772963X25007112"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102282","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ivabradine and Atrial Fibrillation Incidence","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102282"}}